Skip to content
Aperlena

Belgium - Research and development services and related consultancy services - Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures Next Generation Therapeutics for Infectious Diseases

Upcoming Prior information notice No deadline published
Watch this tender

We email you if the deadline moves or a correction is published. Free. Log in

Summary

Machine-generated summary

The buyer is seeking research and development services and related consultancy under multiple sourcing framework contracts. The aim is to speed up the development of promising Next Generation Therapeutics for Infectious Diseases through a competitive, phased development under Pre-Commercial Procurement (PCP). The scope covers innovative therapeutics for viral infections, ARDS or sepsis resulting from infections, including pathogen-targeted and host-targeted therapeutics such as direct-acting and indirect-acting antivirals and novel immune modulators. Small molecules and monoclonal antibodies are excluded. Combination therapies and alternatives to IV administration may also be covered. Broad spectrum, pathogen-agnostic and resistance-counteracting therapeutics are of particular interest. The buyer is located in Belgium. Estimated value, deadline and qualification rules are not stated in the notice; the procedure is a call for tenders.

Description

This call for tenders aims at speeding up the development of promising Next Generation Therapeutics for Infectious Diseases by adopting a competitive development in phases, under Pre-Commercial Procurement (PCP). The scope of the call is expected to cover the development of innovative therapeutics to treat viral infections, ARDS or sepsis resulting from infections, including pathogen-targeted therapeutics (but not small molecules or monoclonal antibodies) and host-targeted therapeutics, among which but not only direct-acting antivirals, indirect-acting antivirals and novel immune modulators. It may also cover innovative combinations therapies and products designed to be administered through alternative routes to IV. Broad spectrum therapeutics, pathogen-agnostic therapeutics and therapeutics that could reduce or counteract the emergence of viral resistance are of particular interest.

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 1 month ago

More from this buyer

Full buyer profile

5 open tenders right now

Who usually wins this buyer's contracts in this sector

Based on 4 awards with a linked company profile over the last 5 years.

Change history

Every time an official source republished this notice with different content. We watch every source we index, including regional copies of the same notice.

  1. Read before bidding
    • Title: "Belgium - Research and development services and related consultancy services - M..." to "Belgium – Research and development services and related consultancy services – M..."
    • Estimated value: Set to €244,000,000
    • Estimated value: Set to €244,000,000

Follow this tender and we email you the moment it changes. Create account

Similar tenders

Market context

Avg. open tender · Research & development
€3,390,052
545 open across Europe right now
Buyer track record on Aperlena
27 notices tracked · 9 awarded
€17,719,420 in awarded contracts

Never miss a tender like this

5 new notices in Research & development in Belgium in the last 7 days. Get an email when new ones appear. Free.

Set up my alert

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
/
Jump to the search box
?
Show these shortcuts
Esc
Close